View Pages
Market Morning: MRNA Downgrade, Boeing $20B Navy Jet Deal, Jabil Earnings
Citi downgrades Moderna after huge rally; Boeing wins $20B Navy fighter jet contract; Jabil posts earnings beat with steady guidance — key Wednesday market movers.
Editorial companion
What stands out
The clip highlights three market-moving headlines in quick succession: Citi downgraded Moderna after a recent parabolic rally, Boeing announced a roughly $20 billion U.S. Navy fighter-jet contract, and Jabil reported an earnings beat with steady guidance that barely moved the stock. The most interesting thread is the contrast between headlines and underlying signals, Moderna is rallying hard even as analysts cut ratings, Boeing’s big contract arrives while its short-term price trend is weak, and Jabil’s solid results failed to spark follow-through in the tape.
View Pages
View Pages
Bullish Gator Snapshot
Current ratings and signals
Boeing (BA)
Bearish
BA rates Bearish overall. The fundamental read is neutral: the company passes 7 of 9 quality tests on the Piotroski F-Score; balance sheet is flagged Distress (Altman Z = 1.40); revenue is growing about 12.3% per year. The technical picture is bearish: price is 22.9% below the 200-day moving average; 15.5% below the 50-day; the 50/200 relationship is in a Death cross. Sentiment is neutral (composite 52/100), based on 3 news articles, 1 TV segment, and 2 qualified videos from recent coverage.
Jabil (JBL)
Bearish
JBL rates Bearish overall. The fundamental read is neutral: the company passes 7 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.56); revenue is growing about 2.3% per year; net income is growing about 25.2% per year. The technical picture is bearish: price is 7.7% below the 200-day moving average; 6.2% below the 50-day; the 50/200 relationship is in a Death cross. Sentiment is bearish (composite 50/100), based on 8 news articles from recent coverage.
Moderna (MRNA)
Neutral
MRNA rates Neutral overall. The fundamental read is neutral: the company passes 1 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 13.60); revenue is declining about 52.3% per year. The technical picture is neutral: price is 148.0% above the 200-day moving average; 17.7% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bearish (composite 24/100), based on 7 news articles, 1 TV segment, and 7 qualified videos from recent coverage.